[Drug selection guided by known and newly diagnosed comorbidities in a multi-risk patient].
The obese patient with osteoarthritis, arterial hypertension, type 2 diabetes, hyperuricaemia, mixed dyslipidaemia and moderate renal insufficiency is commonly seen in clinical practice. Besides life-style changes, the optimal management of such patient requires the use of a polymedication therapy whose choice should take into account not only possible pharmacological synergistic effects to warrant the best protection, but also contra-indications due to the presence of comorbidities or the risk of drug interferences.